Items tagged with Medicines
Cancer drugs might be able to target TB, study finds (post)
TB lesions in the lungs have high levels of proteins that suppress the immune system. Cancer drugs that target these proteins could be used to fight the bacterial infection.
Can drug-resistant TB be reversed with a novel small molecule? Scientists turn to an animal model to find out (post)
Tuberculosis is a major public health concern, an ancient bacterial disease that has claimed the lives of kings, presidents, poets and at least one star of Hollywood's silver screen-era. Yet even now in the 21st century, it's still impossible to shake the scourge. TB kills someone around the globe every 22 seconds, the World Health Organization estimates.
Hundreds of new drug targets to combat TB (post)
Tuberculosis is a stubborn disease, born of yet more stubborn microbes. While many bacterial infections resolve within days of starting antibiotics, tuberculosis often refuses to budge for around six months and, in some cases, may never release its vice grip on the human body. It claimed 1.5 million lives in 2020, second only to COVID-19 among infectious diseases.
New antibiotics could tackle drug-resistant TB (post)
Infection by Mycobacterium tuberculosis kills 1.5 million people worldwide every year. Antibiotics to treat TB exist, but in recent years, multi-drug resistant (MDR), extensively drug-resistant (XDR) and totally drug-resistant (TDR) strains of the bacterium have developed. According to a new study publishing May 31st in the open-access journal PLOS Biology by Ho-Yeon Song of Soonchunhyang University in the Republic of Korea and colleagues, a new class of antibiotics is highly effective against drug-resistant tuberculosis. If validated in clinical trials, the new drug class would represent a major advance in the treatment of tuberculosis.
New TB drug combination trial – hope for shorter treatment (post)
The University of Cape Town’s Lung Institute is conducting a new trial involving BTZ-043 (benzothiazinone DprE1 blocker), a novel TB drug candidate. There are also plans to test BTZ-043 in combination with two other new TB drug candidates. If all goes well, the new drug regimen could reduce TB treatment from the current six months to four.
Regulatory best practices for global access to medicines, including TB medicines (post)
The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) will conduct a three half-days conference Regulatory Best Practices for Global Access to Medicines, Including Anti-TB Medicines on 16-18 August 2022.
Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different (post)
TB, HIV, and hepatitis C virus (HCV) share a global presence and propensity to disproportionately affect marginalized populations. However, over recent decades, many fewer drugs have been brought to market for TB than for the others.
A big step toward treating TB without risking antibiotic resistance (post)
Tuberculosis, an infectious disease that killed 1.5 million people in 2020, is most commonly treated with a cocktail of four drugs that must be taken for up to six months. This treatment plan, however, can have the unintended consequence of leading to antibiotic resistance, both because people may not finish the full course of treatment and, more directly, because one of the drugs can act on bacteria other than Mycobacterium tuberculosis, including components of the intestinal microflora that are critical to health and wellbeing.
Webinar: Choosing TB regimens to advance to late-stage clinical trials (post)
RESIST-TB will host a webinar on 24 October 2022 'Choosing TB regimens to advance to late-stage clinical trials: Using interim (Bayesian) analyses to increase likelihood of success'.
Merck and the Bill & Melinda Gates Medical Research Institute announce licensing agreement for novel TB antibiotic candidates (post)
RAHWAY, N.J., and Cambridge M.A., October 18, 2022 – Merck, (NYSE: MRK), known as MSD outside of the United States and Canada, and the Bill & Melinda Gates Medical Research Institute (Gates MRI) today announced a licensing agreement for two preclinical antibacterial candidates for evaluation as potential components of combination regimens for the treatment of tuberculosis (TB). These candidates were discovered by Merck scientists as part of the TB Drug Accelerator (TBDA). The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB. The initiative was established with support and leadership from the Bill & Melinda Gates Foundation.
Page 13 of 19 · Total posts: 0
←First 12 13 14 Last→